Ángel Rodríguez Sánchez

Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study

Begoña Pérez‐Valderrama, Jóse Ángel Arranz Arija, Ángel Rodríguez Sánchez et al. · Annals of Oncology · 2015 · 36 citations · Full text

Urology, Spazo Study, Genitourinary Cancer +7

Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)

Manuela Schmidinger, Aristotelis Bamias, Giuseppe Procopio et al. · The Oncologist · 2019 · 28 citations · Full text

SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

Javier Cassinello, José Ángel Arranz, Josep M. Piulats et al. · Clinical & Translational Oncology · 2017 · 21 citations · Full text

LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC

Alex Martínez‐Martí, Margarita Majem, Fabrice Barlési et al. · Annals of Oncology · 2021 · 21 citations

Lba42 Coast, Ii Platform Study, Medicine +10

Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)

Juan Manuel Sepúlveda-Sánchez, Miguel Gil‐Gil, Miriam Alonso-García et al. · Targeted Oncology · 2020 · 20 citations

Spanish Group, Neuro-oncology, Phase Ii Trial +8